The company says that many scientists now support the notion that controlling the oxidation of LDL cholesterol is essential for maintaining arterial health.
On April 12 during the SupplySide Science Tour being held in Salt Lake City, UT, Stratum Nutrition’s (St. Louis) manager of pharmacology Joseph L. Evans, PhD, will present information on arterial-health ingredient Artinia.
Titled “Effects of Artinia in Cardiohealth: Oxidized LDL as a Biomarker,” the presentation will cover the benefits of Artinia, which combines soluble and insoluble fibers and supports healthy arteries and overall cardiovascular health.
The company says that many scientists now support the notion that controlling the oxidation of low-density lipoprotein (LDL) cholesterol, and not just the level of LDL cholesterol, is essential for maintaining arterial health. This is because the oxidation of LDL cholesterol within the artery wall leads to a series of inflammatory events that can result in the formation of fatty streaks in the artery tissue, which in time can turn into arterial plaque.
Artinia works as an antioxidant, resulting in a reduced level of oxidized LDL. The ingredient is GRAS affirmed and approved by the EU Commission as a Novel Food ingredient. It is vegetarian and gluten free.
Sirio Pharma launches line of ready-to-market organic gummies and softgels called PureOrganix
August 26th 2024The new line is made up of three gummies and one softgel that are formulated to meet stringent EU-Organic certification criteria, and target women’s health, metabolic health, and heart health.
SourceOne Global Partners to distribute Qualitas Health’s microalgae omega-3 ingredient globally
August 15th 2024SourceOne Global Partners has announced a partnership with Qualitas Health Inc., (dba iwi life) to introduce the company’s trademarked AlmegaPL microalgae omega-3 ingredient to the global marketplace.
Meta-analysis does not find increased risk of bleeding events from omega-3 PUFA consumption
July 8th 2024Researchers reviewed 11 studies and found that there was no difference in the incidence of bleeding events between patients receiving omega-3 PUFAs and those not receiving them. High dose EPA consumption was associated with an elevated but modest risk.